Veracyte Inc

Company Profile

Veracyte Inc had its IPO on 2013-10-30 under the ticker symbol VCYT.

The company operates in the Healthcare sector and Biotechnology industry. Veracyte Inc has a staff strength of 787 employees.

Stock update

Shares of Veracyte Inc opened at $21.88 at the start of the last trading session i.e. 2023-03-24.

The stocks traded within a range of $21.3 - $22.17, and closed at $21.97.

This is a -0.68% slip from the previous day's closing price.

A total volume of 672,113 shares were traded at the close of the day’s session.

In the last one week, shares of Veracyte Inc have slipped by -5.75%.

Veracyte Inc's Key Ratios

Veracyte Inc has a market cap of $1.58 billion, indicating a price to book ratio of 1.9941 and a price to sales ratio of 7.1658.

In the last 12-months Veracyte Inc’s revenue was $296.54 million with a gross profit of $194.95 million and an EBITDA of $-11699000. The EBITDA ratio measures Veracyte Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Veracyte Inc’s operating margin was -12.69% while its return on assets stood at -2.01% with a return of equity of -3.37%.

In Q4, Veracyte Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 19.2%.

Veracyte Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-0.51 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Veracyte Inc’s profitability.

Veracyte Inc stock is trading at a EV to sales ratio of 6.8297 and a EV to EBITDA ratio of -106.0056. Its price to sales ratio in the trailing 12-months stood at 7.1658.

Veracyte Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$1.16 billion

Total Liabilities

$62.61 million

Operating Cash Flow

$-26434000.00

Capital Expenditure

$1.87 million

Dividend Payout Ratio

0%

Veracyte Inc ended 2023 with $1.16 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.16 billion while shareholder equity stood at $1.08 billion.

Veracyte Inc ended 2023 with $4.53 million in deferred long-term liabilities, $62.61 million in other current liabilities, 72000.00 in common stock, $-393717000.00 in retained earnings and $695.89 million in goodwill. Its cash balance stood at $154.25 million and cash and short-term investments were $178.85 million. The company’s total short-term debt was $4,070,000 while long-term debt stood at $0.

Veracyte Inc’s total current assets stands at $248.64 million while long-term investments were $0 and short-term investments were $24.61 million. Its net receivables were $44.02 million compared to accounts payable of $11.91 million and inventory worth $14.29 million.

In 2023, Veracyte Inc's operating cash flow was $-26434000.00 while its capital expenditure stood at $1.87 million.

Comparatively, Veracyte Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$21.97

52-Week High

$32.4

52-Week Low

$14.85

Analyst Target Price

$31.67

Veracyte Inc stock is currently trading at $21.97 per share. It touched a 52-week high of $32.4 and a 52-week low of $32.4. Analysts tracking the stock have a 12-month average target price of $31.67.

Its 50-day moving average was $24.55 and 200-day moving average was $22.97 The short ratio stood at 5.11 indicating a short percent outstanding of 0%.

Around 96.9% of the company’s stock are held by insiders while 10474% are held by institutions.